Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MediWound Ltd.MDWD · Entity 296 | COO & Chief Commercial Officer | August 26, 2026 | August 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MediWound Ltd.
Report date August 26, 2026 · Filed August 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-08-26 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-08-26 · Sale · Disposed 1,865 · Balance 0 F8: The Reporting Person exercised 5,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 1,865 ordinary shares to the Reporting Person. All 1,865 ordinary shares received upon the net exercise were sold on the same day as reported in Table I. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2026-08-27 · Sale · Disposed 1,979 · Balance 0 F9: The Reporting Person exercised 11,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 3,958 ordinary shares to the Reporting Person. All 3,958 ordinary shares received upon the net exercise were sold on the same day as reported in Table I. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2026-08-27 · Sale · Disposed 1,979 · Balance 0 F9: The Reporting Person exercised 11,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 3,958 ordinary shares to the Reporting Person. All 3,958 ordinary shares received upon the net exercise were sold on the same day as reported in Table I. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 4,085 |
Reported balance
Holding disclosure · report date 2026-08-26 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 4,085 F1: The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. F10: There were no transactions effected in respect of the securities reported in the rows marked with this footnote, and the holdings in such rows are being included for informational purposes only. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 3,000 |
Reported balance
Holding disclosure · report date 2026-08-26 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 3,000 F2: The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. F10: There were no transactions effected in respect of the securities reported in the rows marked with this footnote, and the holdings in such rows are being included for informational purposes only. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 3,000 |
Reported balance
Holding disclosure · report date 2026-08-26 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 3,000 F3: The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. F10: There were no transactions effected in respect of the securities reported in the rows marked with this footnote, and the holdings in such rows are being included for informational purposes only. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $8.13 · Expires 2033-12-01 | Direct | 27,000 |
Reported balance
After 2026-08-26 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-26 · Exercise / conversion · Disposed 5,000 · Balance 27,000 F4: The options reported in this row are the remaining outstanding options from a grant of 39,000 options that were granted to the Reporting Person on December 1, 2023 and that have been vesting in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. F8: The Reporting Person exercised 5,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 1,865 ordinary shares to the Reporting Person. All 1,865 ordinary shares received upon the net exercise were sold on the same day as reported in Table I. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $8.13 · Expires 2033-12-01 | Direct | 16,000 |
Reported balance
After 2026-08-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-27 · Exercise / conversion · Disposed 11,000 · Balance 16,000 F4: The options reported in this row are the remaining outstanding options from a grant of 39,000 options that were granted to the Reporting Person on December 1, 2023 and that have been vesting in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. F9: The Reporting Person exercised 11,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 3,958 ordinary shares to the Reporting Person. All 3,958 ordinary shares received upon the net exercise were sold on the same day as reported in Table I. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $12.73 · Expires 2034-02-26 | Direct | 32,681 |
Reported balance
Holding disclosure · report date 2026-08-26 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 32,681 F5: The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. F10: There were no transactions effected in respect of the securities reported in the rows marked with this footnote, and the holdings in such rows are being included for informational purposes only. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $18.54 · Expires 2035-02-11 | Direct | 24,000 |
Reported balance
Holding disclosure · report date 2026-08-26 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 24,000 F6: The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. F10: There were no transactions effected in respect of the securities reported in the rows marked with this footnote, and the holdings in such rows are being included for informational purposes only. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $17.60 · Expires 2036-03-04 | Direct | 31,000 |
Reported balance
Holding disclosure · report date 2026-08-26 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 31,000 F7: The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. F10: There were no transactions effected in respect of the securities reported in the rows marked with this footnote, and the holdings in such rows are being included for informational purposes only. |
Filing footnotes · ownership attribution and instrument terms
F1: The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
F2: The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
F3: The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
F4: The options reported in this row are the remaining outstanding options from a grant of 39,000 options that were granted to the Reporting Person on December 1, 2023 and that have been vesting in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
F5: The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
F6: The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
F7: The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
F8: The Reporting Person exercised 5,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 1,865 ordinary shares to the Reporting Person. All 1,865 ordinary shares received upon the net exercise were sold on the same day as reported in Table I.
F9: The Reporting Person exercised 11,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 3,958 ordinary shares to the Reporting Person. All 3,958 ordinary shares received upon the net exercise were sold on the same day as reported in Table I.
F10: There were no transactions effected in respect of the securities reported in the rows marked with this footnote, and the holdings in such rows are being included for informational purposes only.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 27, 2026 Filed Aug 28, 2026 16:02 UTC | MediWound Ltd. MDWD · Entity 296 | Exercise / conversionStock Option (right to buy ordinary shares) · Derivative | 11,000 | $0.00 Strike: $8.13 | $0.00 |
DisclosureSEC source: 0001178913-26-004299 · ownership.xml · derivative · entry 8 Hess Shmuel · CIK 0002085305 · COO & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Ordinary Shares · 11,000 shares Expires 2033-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: The options reported in this row are the remaining outstanding options from a grant of 39,000 options that were granted to the Reporting Person on December 1, 2023 and that have been vesting in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. F9 · security: The Reporting Person exercised 11,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 3,958 ordinary shares to the Reporting Person. All 3,958 ordinary shares received upon the net exercise were sold on the same day as reported in Table I. F4 · derivative.exercise_date: The options reported in this row are the remaining outstanding options from a grant of 39,000 options that were granted to the Reporting Person on December 1, 2023 and that have been vesting in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. Read SEC document |
| August 27, 2026 Filed Aug 28, 2026 16:02 UTC | MediWound Ltd. MDWD · Entity 296 | SaleOrdinary Shares | 1,979 | $13.13 | $25,976.35 |
DisclosureSEC source: 0001178913-26-004299 · ownership.xml · nonDerivative · entry 3 Hess Shmuel · CIK 0002085305 · COO & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F9 · security: The Reporting Person exercised 11,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 3,958 ordinary shares to the Reporting Person. All 3,958 ordinary shares received upon the net exercise were sold on the same day as reported in Table I. Read SEC document |
| August 27, 2026 Filed Aug 28, 2026 16:02 UTC | MediWound Ltd. MDWD · Entity 296 | SaleOrdinary Shares | 1,979 | $12.72 | $25,172.88 |
DisclosureSEC source: 0001178913-26-004299 · ownership.xml · nonDerivative · entry 2 Hess Shmuel · CIK 0002085305 · COO & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F9 · security: The Reporting Person exercised 11,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 3,958 ordinary shares to the Reporting Person. All 3,958 ordinary shares received upon the net exercise were sold on the same day as reported in Table I. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 16:02 UTC | MediWound Ltd. MDWD · Entity 296 | Exercise / conversionStock Option (right to buy ordinary shares) · Derivative | 5,000 | $0.00 Strike: $8.13 | $0.00 |
DisclosureSEC source: 0001178913-26-004299 · ownership.xml · derivative · entry 7 Hess Shmuel · CIK 0002085305 · COO & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Ordinary Shares · 5,000 shares Expires 2033-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: The options reported in this row are the remaining outstanding options from a grant of 39,000 options that were granted to the Reporting Person on December 1, 2023 and that have been vesting in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. F8 · security: The Reporting Person exercised 5,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 1,865 ordinary shares to the Reporting Person. All 1,865 ordinary shares received upon the net exercise were sold on the same day as reported in Table I. F4 · derivative.exercise_date: The options reported in this row are the remaining outstanding options from a grant of 39,000 options that were granted to the Reporting Person on December 1, 2023 and that have been vesting in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 16:02 UTC | MediWound Ltd. MDWD · Entity 296 | SaleOrdinary Shares | 1,865 | $13.00 | $24,245.00 |
DisclosureSEC source: 0001178913-26-004299 · ownership.xml · nonDerivative · entry 1 Hess Shmuel · CIK 0002085305 · COO & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F8 · security: The Reporting Person exercised 5,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 1,865 ordinary shares to the Reporting Person. All 1,865 ordinary shares received upon the net exercise were sold on the same day as reported in Table I. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.